Therapy-related myeloid neoplasms (t-MN) include myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) occurring as a late effect of chemotherapy and/or radiotherapy for a primary malignancy or for autoimmune diseases. The incidence of this complication has been raising in the past years because of the prolonged survival and the higher number of treated patients. Still, <5% of patients exposed to cytotoxic drugs and radiotherapy develop a t-MN, suggesting an underlying individual susceptibility. Primary malignancies most frequently associated to t-MN are breast cancer and lymphoproliferative diseases. Other recurrent clinical characteristics are presence of multiple primary neoplasms in the same individual and cancer familiarity.2 So far, higher frequency of single-nucleotide variants of detoxification and DNA-repair enzymes, alone or in association, have been reported in t-MN, but none has been validated as significant risk factor in large patient groups.

Fanconi anemia gene variants in therapy-related myeloid neoplasms

FABIANI, ERNESTO;PADELLA, ANTONELLA;MARTINI, MARTA;SANTANGELO, ROSARIA;SIMONETTI, GIORGIA;MANFRINI, MARCO;MARTINELLI, GIOVANNI;LEONE, GIULIA;
2015

Abstract

Therapy-related myeloid neoplasms (t-MN) include myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) occurring as a late effect of chemotherapy and/or radiotherapy for a primary malignancy or for autoimmune diseases. The incidence of this complication has been raising in the past years because of the prolonged survival and the higher number of treated patients. Still, <5% of patients exposed to cytotoxic drugs and radiotherapy develop a t-MN, suggesting an underlying individual susceptibility. Primary malignancies most frequently associated to t-MN are breast cancer and lymphoproliferative diseases. Other recurrent clinical characteristics are presence of multiple primary neoplasms in the same individual and cancer familiarity.2 So far, higher frequency of single-nucleotide variants of detoxification and DNA-repair enzymes, alone or in association, have been reported in t-MN, but none has been validated as significant risk factor in large patient groups.
2015
Voso, M.T.; Fabiani, E.; Zang, Z.; Fianchi, L.; Falconi, G.; Padella, A.; Martini, M.; Li Zhang, S.; Santangelo, R.; Larocca, L.M.; Criscuolo, M.; La Brocca, A.; Cutcutache, I.; Rozen, S.; Simonetti, G.; Manfrini, M.; Martinelli, G.; Hohaus, S.; Leone, G.; Tan, P.; Tenen, D.G.
File in questo prodotto:
File Dimensione Formato  
bcj201544.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 167.72 kB
Formato Adobe PDF
167.72 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/549277
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 30
social impact